Connect Biopharma Holdings Limited (CNTB)
NASDAQ: CNTB · Real-Time Price · USD
2.450
+0.150 (6.52%)
At close: Aug 25, 2026, 4:00 PM EDT
2.460
+0.010 (0.41%)
After-hours: Aug 25, 2026, 7:30 PM EDT
CNTB Revenue
Connect Biopharma Holdings had revenue of $2.77M in the quarter ending June 30, 2026, with 5,666.67% growth. This brings the company's revenue in the last twelve months to $2.95M, up 50.28% year-over-year. In the year 2025, Connect Biopharma Holdings had annual revenue of $64.00K, down -99.75%.
Revenue (ttm)
$2.95M
Revenue Growth
+50.28%
P/S Ratio
52.25
Revenue / Employee
$46,141
Employees
64
Market Cap
154.29M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 64.00K | -25.97M | -99.75% |
| Dec 31, 2024 | 26.03M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Jan 1, 2022 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| LENZ Therapeutics | 21.48M |
| Equillium | 4.39M |
| NRx Pharmaceuticals | 3.39M |
| Milestone Pharmaceuticals | 2.34M |
| Kazia Therapeutics | 1.27M |
| Outlook Therapeutics | -1.16M |
CNTB News
- 9 days ago - Connect Biopharma price target raised to $7 from $6 at Canaccord - TheFly
- 13 days ago - Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 13 days ago - Connect Biopharma Holdings Earnings release: Q2 2026 - Filings
- 13 days ago - Connect Biopharma Holdings Quarterly report: Q2 2026 - Filings
- 6 weeks ago - Connect Biopharma Holdings Slides: Corporate presentation - Filings
- 6 weeks ago - Connect Biopharma initiated with an Outperform at Oppenheimer - TheFly
- 2 months ago - Connect Biopharma initiated with an Overweight at Piper Sandler - TheFly
- 2 months ago - Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma - GlobeNewsWire